

Norio Hanafusa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2664285/publications.pdf>

Version: 2024-02-01

18
papers

560
citations

1305906

8
h-index

1113639

15
g-index

18
all docs

18
docs citations

18
times ranked

841
citing authors

#	ARTICLE	IF	CITATIONS
1	Nephrology in Japan. , 2021, , 345-360.		0
2	Granulocyte and monocyte apheresis therapy for patients with active ulcerative colitis associated with COVID-19. Intestinal Research, 2021, , .	1.0	2
3	Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study. International Journal of Clinical Oncology, 2021, 26, 1130-1138.	1.0	5
4	Safety and efficacy of cell-free and concentrated ascites reinfusion therapy against cirrhotic ascites in comparison with malignancy-related ascites. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 3224-3232.	1.4	5
5	Biochemical evaluation of processed ascites in patients undergoing cell-free and concentrated ascites reinfusion therapy. Therapeutic Apheresis and Dialysis, 2020, 24, 516-523.	0.4	2
6	Strategies for the Super-Aged Dialysis Population: Survival Benefits or Alternative Goals?. Blood Purification, 2019, 47, 95-105.	0.9	0
7	Effects of tolvaptan on renal function in chronic kidney disease patients with volume overload. International Journal of Nephrology and Renovascular Disease, 2018, Volume 11, 235-240.	0.8	2
8	Heterogeneity of clinical indices among the older dialysis population—a study on Japanese dialysis population. Renal Replacement Therapy, 2017, 3, .	0.3	7
9	Efficacy of Substance Removal by Immunoabsorption With a Selective Plasma Separator. Therapeutic Apheresis and Dialysis, 2017, 21, 218-225.	0.4	3
10	Is There a Role for Diaphoresis Therapy for Advanced Chronic Kidney Disease Patients?. , 2017, 27, 295-302.		10
11	Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: Post-marketing surveillance results. PLoS ONE, 2017, 12, e0177303.	1.1	36
12	The characteristics of the older dialysis population—heterogeneity and another type of altered risk factor patterns. Renal Replacement Therapy, 2017, 3, .	0.3	12
13	Testing the Feasibility and Usability of a Novel Smartphone-Based Self-Management Support System for Dialysis Patients: A Pilot Study. JMIR Research Protocols, 2017, 6, e63.	0.5	33
14	An Overview of Regular Dialysis Treatment in Japan (As of 31 December 2013). Therapeutic Apheresis and Dialysis, 2015, 19, 540-574.	0.4	275
15	Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites. International Journal of Clinical Oncology, 2015, 20, 623-628.	1.0	33
16	Japanese society for dialysis therapy renal data registry—a window through which we can view the details of Japanese dialysis population. Kidney International Supplements, 2015, 5, 15-22.	4.6	70
17	Age and anemia management: relationship of hemoglobin levels with mortality might differ between elderly and nonelderly hemodialysis patients. Nephrology Dialysis Transplantation, 2014, 29, 2316-2326.	0.4	29
18	Single Center Experience of Cell-Free and Concentrated Ascites Reinfusion Therapy in Malignancy Related Ascites. Therapeutic Apheresis and Dialysis, 2014, 18, 87-92.	0.4	36